News zum Sektor Gesundheit aus Schweden

 

STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection......

In the second quarter of 2025, CHOSA Oncology AB (publ) ("Chosa" or the "Company") issued 7,951,740 warrants of series TO2 in connection with an issue of units. The exercise period commenced on 1 July 2026, and will end tomorrow, 14 July 2026. Members of the executive management have subscribed for a total of 550,527 shares. Subscription from executive management The following members of the executive management have subscribed, directly or through companies, in the ongoing warrant exercise: · Peter Buhl Jensen (CEO) and Ulla Hald Buhl (COO) - 377,073 shares · Claus Frisenberg...

UPPSALA, SE / ACCESS Newswire / July 13, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) invites investors, analysts, and media to presentations of the second quarter report for 2026 on July 16. The report ......

Former Scandinavian ChemoTech AB, has completed the name change to Neem's Hill AB (“Neem's Hill” or “the Company”), which was resolved at the Annual General Meeting held on 5 May 2026. The name change has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket). As a result, the Company's ticker for trading on Nasdaq First North Growth Market will be changed to NEEMS as of 2026-07-13. The name change to Neem's Hill AB is part of the Company's strategic expansion of its existing business activities and will be implemented gradually to ensure consistency and clarity...

STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous......

MALMÖ, SE / ACCESS Newswire / July 12, 2026 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (STO:ACE), a biopharmaceutical company focused on improving the lives of people living with rare ca......

Stockholm, Sweden, July 12, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer's disease. The findings support a fully subcutaneous treatment pathway from initiation through maintenance treatment, offering greater convenience and flexibility for patients and care...

BiBBInstruments AB ("BiBB" or the "Company") is issuing a correction to the press release regarding an exclusive distribution agreement with Palex Medical Spain, published on July 9, 2026. The correction relates solely to the inclusion of the MAR statement pursuant to the EU Market Abuse Regulation (MAR). Apart from this, the press release remains unchanged. The Swedish version of the press release included the MAR statement and was published correctly. The corrected version of the press release follows below. BiBB signs exclusive distribution agreement with Palex Medical Spain...

EQL Pharma AB (publ) will publish its interim report for the first quarter, 2026/27, on Friday, 7[th ]August. At 10.00 (CET) 7[th] August, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/nj5tmxzh Date and time August 7[th], 2026, at 10.00 (CET) the presentation...

10th  July 2026 – CHOSA Oncology AB ("CHOSA" or the "Company") today announces the appointment of Bill Cronin to support the Company's commercial expansion in the United States. Bill Cronin will lead CHOSA's US business development and commercialization activities as the Company advances the market introduction of Platin-DRP® in the world's largest oncology diagnostics market. Bill Cronin will be based in Kendall Square, Boston the most important oncology centre in the US. The appointment follows CHOSA's recent clinical progress, including the presentation of data from the ETOP/EORTC...

Qiagen NV, the European molecular testing company, is drawing early takeover interest from firms including EQT AB and Advent, people familiar with the matter said....

BiBBInstruments AB ("BiBB" or the "Company"), developer of EndoDrill[®] – the world's first market-cleared powered biopsy instrument for endoscopy – announces today that the Company has signed its first European commercial distribution agreement for EndoDrill[®] GI with Palex Medical S.A.U. ("Palex Spain"). Under the agreement, Palex Medical Spain receives exclusive rights to market, sell and commercialize EndoDrill[®] GI in Spain. The agreement is intended to serve as a foundation for further commercial expansion within additional European regions of the Palex network. Preparations for the...

Lund, Sweden, 8 July, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January - June 2026 on 22 July, 2026. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST / 8:00 AM EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Adam Cutler, CFO, Richard Philipson, CMO, and Maria Törnsén, COO and President U.S. During the call, management will review the Company's interim financial results and provide a business and pipeline update. The presentation will be held in English. Slides used in the...

The shareholders of Biosergen AB, Reg. No. 559304-1295 (the "Company" or “Biosergen”), are invited to attend the extraordinary general meeting to be held on 6 August 2026 at 16:00 at BAHR Advokatbyrå at Birger Jarlsgatan 16,  Stockholm. Registration for the meeting begins at 15:30. Right to participate Shareholders wishing to participate in the extraordinary general meeting must: · be listed in the Company's share register kept by Euroclear Sweden AB as of 29 July 2026; and · have given a notice of their intent to participate to the Company no later than on 31 July 2026. The...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR DISCLOSURE WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The Board of Directors of Episurf Medical AB (publ) ("Episurf" or...

Episurf Medical AB (publ) (“Episurf” or the “Company”) announced on 5 June 2026 the acquisition of a property portfolio of 30 properties in Södermanland and Östergötland, with an agreed property value of SEK 920 mn. Closing of the portfolio takes place in several parts. The first partial closing is carried out today, 7 July 2026, and comprises properties with an agreed property value of SEK 301 mn. The partial closing in brief The partial closing comprises shares in the companies, and indirectly the subsidiaries and properties, that under a supplemental agreement to the original share...

UPPSALA, SE / ACCESS Newswire / July 7, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica International AB today announced the appointment of Maria Ekdahl as Chief Financ......

UPPSALA, SE / ACCESS Newswire / July 7, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica International AB today announced the appointment of Maria Ekdahl as Chief Financ......

UPPSALA, SE / ACCESS Newswire / July 7, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announces an exp......

A Neonatal Critical Care Nursing Training Initiative has been launched in India to address the growing need for skilled neonatal nurses and improve outcomes for newborns. The program, which uses a blended online–offline model to train 1,500 nurses, is supported by global medtech company Getinge. [image] "We are proud to support this initiative as part of our Corporate Social Responsibility program, which reflects our broader commitment to helping save lives and strengthening healthcare systems. Strengthening neonatal care capabilities is a priority for India, and initiatives like this...